AbbVie

AbbVie was founded by Abbott Laboratories in 213 and is based in Chicago IL. The firm partners with developmental-stage biotech companies and is actively seeking to in-license therapeutic assets. AbbVie generally seeks global rights to assets and will consider partnerships worldwide, the firm licenses assets opportunistically with no set rate of allocations. AbbVie also has a venture arm that makes equity investments AbbVie Venture & Early-Stage Collaborations.
Kevin Lynch
Vice President Search and Evaluation 

Becton Dickinson (BD)

BD (Becton Dickinson and Company) based in Franklin Lakes NJ is a leading medical technology company that partners with customers and stakeholders to address many of the world?s most pressing and evolving health needs. Their innovative solutions are focused on improving drug delivery enhancing the diagnosis of infectious diseases and cancers supporting the management of diabetes and advancing cellular research. The firm has nearly 3 associates in 5 countries who strive to fulfill our purpose of ?Helping all people live healthy lives? by advancing the quality accessibility safety and affordability of healthcare around the world. For more information please visit www.bd.com. BD partners with companies from their formation through to commercialization including expansion of operations and channel access. BD considers a variety of engagement models including research collaborations licenses investments and acquisition when partnering with companies aligned with BD?s core businesses and new areas of strategic interest seeking opportunities from around the globe.
Albert Lauritano
Director Strategic Technology Partnerships 

Boehringer Ingelheim

Boehringer Ingelheim was founded in 1885 and is based in Ingelheim am Rhein Germany. The firm invests by means of in-licensing and acquisitions and is primarily focused on respiratory diseases cardiovascular diseases metabolic diseases oncology diseases of the central nervous system and immunology. Boehringer Ingelheim also invests in veterinary medicine.

Imran Nasrullah
Director Innovation Sourcing 

Cydan

Cydan is an orphan drug accelerator that was founded in 213 and is based in Cambridge MA. The firm has raised $26 million dollar to derisk therapeutic assets targeting orphan indications (excluding oncology). The firm looks to option/in-license assets and form subsidiary companies around them. Cydan then derisks the assets conducting all the necessary IND enabling activities. Cydan?s investment syndicate including NEA Pfizer Ventures Lundbeck Venturefonds Bay City Alexandria then has the option to fund the NEWCo Series A round to human proof of principle Cydan is also performing due diligence on companies that are interested in receiving investment from the company's syndicate. Cydan is currently considering pre-clinical and clinical assets worldwide.
Chris Adams
CEO 

Johnson & Johnson (Medical Devices)

Johnson & Johnson (J&J) was founded in 1886 and is based in New Brunswick NJ with an Innovation Center in Cambridge MA. The firm invests in a variety of fields within the life science sector including medical devices. J&J?s medical device investments are highly varied in both size and structure, the structure may involve milestone payments or may be an equity investment. J&J is interested in early stage medical device companies located globally.

Ibraheem Badejo
Senior Director New Ventures 

Johnson & Johnson Innovation United States

Johnson & Johnson (J&J) was founded in 1886 and is based in New Brunswick, NJ, with an Innovation Center in Cambridge, MA. The firm invests in a variety of fields within the life science sector, including medical devices. J&J’s medical device investments are highly varied in both size and structure; the structure may involve milestone payments, or may be an equity investment. J&J is interested in early stage medical device companies located globally.

Thorsten Melcher
New Ventures 

Medtronic United States

Medtronic was founded in 1949 and is based in Minneapolis Minnesota. Medtronic makes strategic investments and acquisitions in the medical device sector and is focused on cardiovascular diseases diabetes diseases of the nervous system (including Parkinson's disease and dystonia) and musculoskeletal conditions. The firm has acquired a number of medical technology and biotechnology companies. Medtronic is also interested in orthopedic products sports health products and telehealth/connected medical devices (particularly consumer apps for health management). Medtronic also makes grants to non-profit organizations. Instructions on applying for investment or grants can be found at Innovate With Medtronic: http://www.medtronic.com/innovation/innovate-with-medtronic.html

Conrad Wang
Senior Director Corporate Development 
Lawrence Cho
Senior Director, Corporate Strategy & Business Development 

Novartis Swaziland

Novartis is a large pharmaceutical company formed in 1996 and based in Basel, Switzerland. Novartis is an active investor in emerging life science companies via in-licensing, strategic partnerships, and acquisitions. Novartis also has a corporate VC fund (Novartis Venture Fund). 

Novartis has seven divisions, all of which accept collaboration proposals athttps://partnering.novartis.com

Novartis Pharmaceuticals is the largest division of Novartis; the division seeks innovative therapeutics that have attained proof of concept in humans, drug delivery technologies, process scale-up/development technologies, and drug manufacturing technologies. Novartis Pharmaceuticals also seeks molecular diagnostics in the oncology field and companion diagnostics that are connected with drug treatments. In addition to in-licensing, Novartis Pharmaceuticals is interested in joint regional commercialization for therapeutic products that are on the market. 

Novartis Institutes for Biomedical Research focuses on early-stage compounds and research technologies (including software, assay tools, disease models, screening and imaging tools, as well as therapeutic discoveries at the pre-proof of concept stage). 

Novartis Vaccines & Diagnostics seeks vaccines in late-stage clinical trials or on the market, vaccine development candidates, and vaccine-related technologies such as delivery, formulation, and adjuvants. 

Novartis Consumer OTC seeks OTC products and prescription products that could be switched to OTC status. Additionally Novartis OTC is interested in scientifically proven nutraceuticals and dietary supplements, innovative packaging technology, drug delivery devices or enabling technology platforms. The fund also invests in medical devices. Indications that Novartis OTC invests in include respiratory diseases, digestive health, pain, analgesics, diseases of the skin, and behavioral disorders (smoking-cessation). 

Novartis Animal Health seeks opportunities in the veterinary, agbio and aquaculture sectors. Indications of interest include musculoskeletal diseases (arthritis), renal diseases, heart disease and allergies in pets, and infectious and parasitic diseases in livestock. Subsectors of interest include animal vaccines and bioprotection (insecticides, fly control). Additionally Novartis Animal Health is interested in drug delivery in animals. 

Sandoz focuses on generics and is also interested in anti-infectives and injectable oncology drugs. 

Alcon focuses on treatments for diseases of the eye, and is interested in therapeutic products, surgical products and over-the-counter ophthalmic products such as contact lenses and lens care products.

Avi Spier

Novo Nordisk

Novo Nordisk was founded in 1923 and is based in Bagsvaerd Denmark with additional R&D sites in Seattle WA Beijing China and Bangalore India. The firm is actively seeking to in-license assets and also forms research collaborations and co-marketing and distribution partnerships with other biotech companies. Novo Nordisk is focused on developing protein and peptide therapeutics and protein delivery devices. The firm has also in-licensed antibodies. Indications of interest include metabolic disorders blood and immune disorders growth disorders and inflammatory disorders. Within the inflammation fieldthe firm is particularly targeting therapies based on cytokines and on molecules on the surface of cells involved in immune regulation. The firm is interested in certain orphan conditions. In addition to partnering and in-licensing Novo Nordisk has a corporate venture fund Novo AS. The firm also offers research grants and resources for studies into Novo Nordisk's products.
Charles Gray
Sourcing Director 
Tomas Landh
Director